Copyright
©The Author(s) 2021.
World J Gastroenterol. Sep 7, 2021; 27(33): 5502-5519
Published online Sep 7, 2021. doi: 10.3748/wjg.v27.i33.5502
Published online Sep 7, 2021. doi: 10.3748/wjg.v27.i33.5502
Figure 2 Coronavirus disease 2019 case fatality rate and nonalcoholic fatty liver disease prevalence.
Mexico 8.5%, Peru 3.6%, Italy 3.5%, South Africa 2.9%, Indonesia 2.8%, United Kingdom 2.7%, Colombia 2.6%, Argentina 2.5%, Germany 2.5% and Brazil 2.5%. The prevalence of nonalcoholic fatty liver disease in those countries is indicated by the colored circles.
- Citation: Campos-Murguía A, Román-Calleja BM, González-Regueiro JA, Hurtado-Díaz-de-León I, Solís-Ortega AA, Flores-García NC, García-Juárez I, Ruiz-Margáin A, Macías-Rodríguez RU. Clinical perspectives, assessment, and mechanisms of metabolic-associated fatty liver disease in patients with COVID-19. World J Gastroenterol 2021; 27(33): 5502-5519
- URL: https://www.wjgnet.com/1007-9327/full/v27/i33/5502.htm
- DOI: https://dx.doi.org/10.3748/wjg.v27.i33.5502